Quest Diagnostics launches COVID workplace testing products
Reprints
Quest Diagnostics on Wednesday announced a new suite of COVID-19 workplace testing products aimed at helping employers ensure safety among workers.
The return to work services aim to provide large-scale workforce COVID-19 testing and are designed to help organizations test employees for the COVID-19 virus and its antibodies, the Secaucus, New Jersey-based firm said in a statement.
Both types of tests provide insights into disease risk for individuals and populations, according to Quest, which also aims to keep employers educated on disease updates and the evolving landscape of testing.
To accommodate expected demand, Quest said it is scaling up its COVID-19 lab operations and expects to have capacity to perform about 150,000 molecular diagnostic tests a day by the end of June, compared with about 80,000 of these tests a day currently. The company also has capacity to perform about 200,000 antibody tests a day, according to the statement.
Read Next
-
Quest Diagnostics to consider job seekers with criminal histories
Quest Diagnostics Inc. will pay a $70,000 penalty and no longer automatically disqualify job applicants with prior arrests or criminal convictions as part of a settlement agreement with the New York attorney general's office.
Related Stories
-
Quest Diagnostics to consider job seekers with criminal histories
-
-
Clinical lab Quest announces collection agency’s data breach
